Immunohistochemical analysis of beta-defensin-2 expression in human lung tumors

The aim of this paper is to present research was directed on analysis of the expression patterns of human beta-defensin-2 (hBD-2) in human lung tumors.

Gespeichert in:

Bibliographische Detailangaben
Datum:	2010
Hauptverfasser:	Shestakova, T., Zhuravel, E., Bolgova, L., Zaitsev, S., Efanova, O., Soldatkina, M., Pogrebnoy, P.
Format:	Artikel
Sprache:	English
Veröffentlicht:	Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2010
Schriftenreihe:	Experimental Oncology
Schlagworte:	Original contributions
Online Zugang:	http://dspace.nbuv.gov.ua/handle/123456789/32309
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!
Назва журналу:	Digital Library of Periodicals of National Academy of Sciences of Ukraine
Zitieren:	Immunohistochemical analysis of beta-defensin-2 expression in human lung tumors / T. Shestakova, E. Zhuravel, L. Bolgova, S. Zaitsev, O. Efanova, M. Soldatkina, P. Pogrebnoy // Experimental Oncology. — 2010. — Т. 32, № 4. — С. 273–276. — Біліогр.: 10 назв. — англ.

Institution

Digital Library of Periodicals of National Academy of Sciences of Ukraine

id	irk-123456789-32309
record_format	dspace
spelling	irk-123456789-323092012-04-17T12:24:45Z Immunohistochemical analysis of beta-defensin-2 expression in human lung tumors Shestakova, T. Zhuravel, E. Bolgova, L. Zaitsev, S. Efanova, O. Soldatkina, M. Pogrebnoy, P. Original contributions The aim of this paper is to present research was directed on analysis of the expression patterns of human beta-defensin-2 (hBD-2) in human lung tumors. 2010 Article Immunohistochemical analysis of beta-defensin-2 expression in human lung tumors / T. Shestakova, E. Zhuravel, L. Bolgova, S. Zaitsev, O. Efanova, M. Soldatkina, P. Pogrebnoy // Experimental Oncology. — 2010. — Т. 32, № 4. — С. 273–276. — Біліогр.: 10 назв. — англ. 1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/32309 en Experimental Oncology Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
institution	Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection	DSpace DC
language	English
topic	Original contributions Original contributions
spellingShingle	Original contributions Original contributions Shestakova, T. Zhuravel, E. Bolgova, L. Zaitsev, S. Efanova, O. Soldatkina, M. Pogrebnoy, P. Immunohistochemical analysis of beta-defensin-2 expression in human lung tumors Experimental Oncology
description	The aim of this paper is to present research was directed on analysis of the expression patterns of human beta-defensin-2 (hBD-2) in human lung tumors.
format	Article
author	Shestakova, T. Zhuravel, E. Bolgova, L. Zaitsev, S. Efanova, O. Soldatkina, M. Pogrebnoy, P.
author_facet	Shestakova, T. Zhuravel, E. Bolgova, L. Zaitsev, S. Efanova, O. Soldatkina, M. Pogrebnoy, P.
author_sort	Shestakova, T.
title	Immunohistochemical analysis of beta-defensin-2 expression in human lung tumors
title_short	Immunohistochemical analysis of beta-defensin-2 expression in human lung tumors
title_full	Immunohistochemical analysis of beta-defensin-2 expression in human lung tumors
title_fullStr	Immunohistochemical analysis of beta-defensin-2 expression in human lung tumors
title_full_unstemmed	Immunohistochemical analysis of beta-defensin-2 expression in human lung tumors
title_sort	immunohistochemical analysis of beta-defensin-2 expression in human lung tumors
publisher	Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
publishDate	2010
topic_facet	Original contributions
url	http://dspace.nbuv.gov.ua/handle/123456789/32309
citation_txt	Immunohistochemical analysis of beta-defensin-2 expression in human lung tumors / T. Shestakova, E. Zhuravel, L. Bolgova, S. Zaitsev, O. Efanova, M. Soldatkina, P. Pogrebnoy // Experimental Oncology. — 2010. — Т. 32, № 4. — С. 273–276. — Біліогр.: 10 назв. — англ.
series	Experimental Oncology
work_keys_str_mv	AT shestakovat immunohistochemicalanalysisofbetadefensin2expressioninhumanlungtumors AT zhuravele immunohistochemicalanalysisofbetadefensin2expressioninhumanlungtumors AT bolgoval immunohistochemicalanalysisofbetadefensin2expressioninhumanlungtumors AT zaitsevs immunohistochemicalanalysisofbetadefensin2expressioninhumanlungtumors AT efanovao immunohistochemicalanalysisofbetadefensin2expressioninhumanlungtumors AT soldatkinam immunohistochemicalanalysisofbetadefensin2expressioninhumanlungtumors AT pogrebnoyp immunohistochemicalanalysisofbetadefensin2expressioninhumanlungtumors
first_indexed	2025-07-03T12:49:26Z
last_indexed	2025-07-03T12:49:26Z
_version_	1836630112961822720
fulltext	Experimental Oncology 32, 273–276, 2010 (December) 273 Lung cancer is a leading cause of cancer-related death worldwide. That’s why numerous studies are di- rected on estimation of etiology of this disease, search for tumor markers, and development of new strategies for lung cancer treatment. It is well recognized now that the etiology of lung cancer is closely related to smoking habits and is often associated with chronic pulmonary inflammation and underlying immune dysfunction. However, little is known yet about involvement of in- nate immunity molecules, in particular, defensins, in lung tumorigenesis. Defensins — cationic antimicrobial peptides — are important components of mucosal immunity which two major functions are thought to be direct antimi- crobial action and modulation of innate and adaptive immunity in response to pathogens. According to accumulated evidences, expression of some alpha- or beta-defensins may be altered or deregulated in different tumor types, and these antimicrobials could play a complex and poorly understood role in cancer pathogenesis either promoting or suppressing tumor cell growth [1, 2]. In normalcy, defensins participate in antimicrobial protection of respiratory tract along with other defense molecules [3]. Mailfunction or altered expression of these peptide antibiotics has been well documented in a number of chronic lung pathologies, in particular, cystic fibrosis, reactive airway disease, tuberculosis and many other lung infections [4]. There are some data evi- dencing on reduced levels of beta-defensin-2 (hBD-2) in sputum and pharyngeal washes of smokers versus nonsmokers with acute pneumonia [5] what points on possible smoking-dependent down-regulation of this peptide in airway epithelium. At the same time, up-to- date there are scarce data for defensin expression pat- terns in lung cancer. In our recent pilot study [6] we have recorded an altered expression of hBD-1-4 mRNAs in lung cancer samples versus normal lung tissue. In this regard we aimed to analyze further the expression patterns of hBD-2 in human lung tumor samples using immunohistochemical approach. MATERIALS AND METHODS In the study, 31 samples of surgically resected human lung tumors of different histological type were studied. The tissue samples were obtained during the surgical treatment of lung cancer patients cured in the Thoracic Department of National Cancer Institute (Kyiv, Ukraine) in 2001–2008 (Head of the Dept., prof. V.L.Ganul). Immediately after surgical removal, tissue samples were placed in liquid nitrogen and stored at -70 oC until use. The patients did not receive chemo- or radiotherapy prior to the surgery. All patients provided an informed written consent to perform the study, and the present research was approved by Ethic Board of the Institute. Histological type and differentiation grade of lung tumors has been estimated by clinical patholo- gists (National Cancer Institute, Dept. Pathol. Anat. Dr. E.N. Kovalchuk and Dr. I.N. Troitskaya). From 31 lung tumor samples, 1 tumor was diagnosed as small-cell lung cancer (SCLC), and 30 — as non-small cell lung cancer (NSCLC). The last group of tumors included 1 case of clear cell large cell lung cancer, 9 cases of squamous cell carcinoma (SCC), and 20 cases of ad- enocarcinoma (AC). The clinico-pathological charac- teristics of lung cancer cases are presented in Table 1. Immunohistochemical analysis. Tumor tissue samples were fixed in 4% formaldehyde for 24 h at room temperature, then dehydrated in 50%, 70%, 80%, 90%, 96% spirits, treated with chloroform, saturated with paraffin at 56 оС for 30 min and placed in paraffin IMMUNOHISTOCHEMICAL ANALYSIS OF BETA- DEFENSIN-2 EXPRESSION IN HUMAN LUNG TUMORS T. Shestakova1,, E. Zhuravel1, L. Bolgova2, S. Zaitsev2, O. Efanova1, M. Soldatkina1, P. Pogrebnoy1 1R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of NAS of Ukraine, Vasylkivska str. 45, Kyiv 03022, Ukraine 2National Cancer Institute, Ministry of Health of Ukraine, Lomonosova str. 33/43, Kyiv 03022, Ukraine Aim: The present research was directed on analysis of the expression patterns of human beta-defensin-2 (hBD-2) in human lung tumors. Materials and Methods: Specimens of surgically resected human lung tumors (n = 31) of different histological type (1 case of small cell lung cancer, and 30 cases of non-small cell lung cancer (1 case of clear cell carcinoma, 9 cases of squamous cell carci- noma (SCC), and 20 cases of adenocarcinoma (AC)) were analyzed for expression of hBD-2 with the use of immunohistochemical analysis. Results: Immunohistochemical analysis has revealed that all lung tumor samples independently on their histological type express hBD-2 peptide, however at different levels (from < 5% to 100% cells). According to our observations, low-differentiated AC differs from moderately differentiated AC by significantly lower hBD-2 expression levels (p < 0.05). No correlation between hBD-2 expression patterns and PCNA or Bcl-2 expression has been found. Conclusion: Human beta-defensin-2 expression levels may depend on differentiation grade of lung adenocarcinoma. Key Words: human beta-defensin-2, human lung tumors, lung squamous cell carcinoma, adenocarcinoma, expression. Correspondence: Fax: +380443581656; E-mail: pogrebnoy@onconet.kiev.ua Abbreviations used: AC — adenocarcinoma; hBD-2 — human beta- defensin-2; HD — high differentiation; LD — low differentiation; MD — moderate differentiation; NSCLC –non-small cell lung cancer; SCC — squamous cell carcinoma; SCLC — small-cell lung cancer. Exp Oncol 2010 32, 4, 273–276 274 Experimental Oncology 32, 273–276, 2010 (December) blocks. 5 µm tissue slides were prepared with the use of microtom REICHERT-JUNG Mod. 1140/Autocut. Immunohistochemical analysis of protein expres- sion has been performed on paraffin slides with the use of a number of primary antibodies listed below, EnVision System and DAB reagent (DAKO, Denmark). The slides were twice deparaffinized with xylol (by 20 min), twice washed with 96% ethanol by 10 min, and washed with distilled water. The slides were placed in citrate buffer for 30 min and incubated in water bath at 95 ̊ С. To block endogenous peroxidase activity, the slides were treated with Peroxidase-Blocking Reagent (DAKO, Denmark) according to instructions of the manufacturer. Incubation with primary antibodies (rat polyclonal anti-hBD-2-Abs (Santa-Cruz, USA) 1 : 100; mouse monoclonal anti-PCNA-Abs (Dako, Denmark) — 1 : 200; mouse monoclonal anti-Bcl-2 (Dako, Den- mark) — 1 : 200) was carried out for 1 h at room tem- perature in humidified atmosphere. To detect binding of primary antibodies, the slides were incubated with visualization system EnVision System (DAKO, Denmark) for 1 h at room temperature in humidified atmosphere. Then peroxidase activity was developed using diaminobenzidine solution (DAB, DakoCytoma- tion, Denmark). Cell nuclei were stained with Meyer’s hematoxylin. As negative control, the slides treated with normal mouse serum followed by DAB, were used. Microscopic examination was done with the use of Carl Zeiss Jena microscope (Germany). The level of protein expression was evaluated by the percent of positive cells or/and by intensity of immunostaining with the use of H-score (counted as follows: H-score = 1 x W + 2 x M + 3 x S, where W, M, S are the percents of cells with weak, moderate and strong staining intensity respectively). Statistical analysis. The statistical significance of the differences between the values (percent of hBD- 2-positive cells, expressed as M±m) was assessed by the Student’s t-test. Values p < 0.05 were considered statistically significant. RESULTS In our research we have studied expression of hBD-2 in 31 lung tumor tissue samples from the same patients. In order to find possible association of hBD-2 expression with the processes of lung cell proliferation or apoptosis, expression of proliferation cell nuclear antigen (PCNA) and antiapoptotic Bcl- 2 protein has been studied as well. Lung tumor samples were represented by histologi- cally heterogenous group composed from 1 sample of SCLC and 30 samples of NSCLC; the latest group was composed from 1 case of clear cell large cell, 9 cases of SCC (8 low differentiatied (LD) tumors, 1 moder- ately differentiated (MD) tumors), and 20 cases of AC (6 LD AC, 6 MD AC, 2 of MD/LD AC, 1 case of mixed AC + SCC type, 1 case of papillary cancer, 2 cases of bronchoalveolar highly differentiatied (HD) cancer, and 2 cases of AC with the regions of clear cell carcinoma) (Table 1). Table 1. The data for lung cancer patients and lung tumor samples used in the study N Case Gen- der Age TNM clas- sification Histological type Differ- entiation grade Addition- al infor- mation 1 A M 52 T2N0M0 Small cell lung cancer PL 2 B M - T2N0M0 Clear cell large cell lung cancer PL 3 C1 M 62 T2N0M0 SCC LD CL 4 C2 M 72 T2N2M1 SCC LD PL 5 C3 M 68 T1N0M0 SCC LD PL 6 C4 M 58 T2N2M0 SCC LD PL 7 C5 M 68 T2N0M0 SCC LD PL 8 C6 M 78 T2N0M0 SCC LD PL 9 C7 M 57 T2N1M0 SCC LD PL 10 C8 M 57 T2N0M0 SCC LD CL 11 C10 M 50 T2N1M0 SCC MD PL 12 D1 F 67 T2N0M0 AC LD PL 13 D2 M 72 T3N2M0 AC MD PL 14 D3 M 57 T2N0M0 Papillary AC with mucus production LD PL 15 D4 M 59 T2N0M0 AC MD PL 16 D6 M 54 T2N1M0 AC MD PL 17 D7 F 54 T1N0M0 AC LD PL 18 D8 M 55 T2N0M0 AC LD PL 19 D9 M 56 T2N2M0 AC LD PL 20 D10 M 41 T1N0M0 AC LD PL 21 D11 M 76 T2N1M0 AC with regions of solid clear cell cancer LD PL 22 D12 F 63 T2N1M0 AC MD/LD PL 23 D13 M 44 T2N1M0 AC MD/LD PL 24 D14 M 40 T2N1M0 AC MD PL 25 D15 M 65 T2N1M0 Mixed type (AC + SCC) PL 26 D16 M 54 T2N2M0 AC MD PL 27 D17 F 64 T2N2M0 AC MD PL 28 D18 M 69 T3N0M0 AC LD PL 29 D19 F 63 T1N0M0 Bronchoalveolar cancer HD PL 30 D20 F 60 T1N0M0 Bronchoalveolar cancer HD PL 31 D21 M 63 T2N2M0 AC with regions of solid clear cell cancer LD PL Notes: tumor differentiation: LD — low-differentiated; MD — moderately-dif- ferentiated; HD — highly-differentiated; SCC — squamous cell carcinoma; AC — adenocarcinoma; PL — peripheral localization, CL — central localization. The study has been performed on paraffin em- bedded tissue blocks of the lung tumors with the use of immunohistochemical approach (Table 2, Fig. 1). Immunohistochemical analysis has revealed that the studied SCC cases of peripheral localization are characterized by moderate to very-high expression of hBD-2 (6 from 7 cases), while 2 cases of SCCs local- ized in bronchus express low levels of hBD-2 protein (< 10%). High percent of cells expressing PCNA or/and Bcl-2 proteins was detected just in 1/3 of SCC cases. Immunohistochemical analysis of hBD-2 expres- sion in AC samples has shown that AC of LD grade differs from AC of MD grade by lower hBD-2 expres- sion (p < 0.05) (Table 2, Fig. 1). PCNA and Bcl-2 ex- pression levels differ between the AC samples in a wide range (however, both markers were negative in HD bronchoalveolar cancer). There was observed no significant correlation between expression levels of mentioned above markers. Experimental Oncology 32, 273–276, 2010 (December) 275 Table 2. Immunohistochemical analysis of hBD-2, PCNA, Bcl-2 expres- sion in human lung tumor samples № Case Expression level hBD-2 PCNA Bcl-2 % positive cells H-scoring % positive cells % positive cells Small cell lung cancer 1 A < 5% 5 90% 80% Non-small cell lung cancer: Clear cell large cell lung cancer 2 B 15% 15 95% 50% Squamous cell carcinoma (LD) 3 C1 10% 10 15% 30% 4 C2 20% 25 20% 7% 5 C3 58% 130 32% 25% 6 C4 45% 85 55% 60% 7 C5 100% 241 64% 60% 8 C6 50% 118 - 6% 9 C7 100% 200 0.5% 5% 10 C8 10% 15 20% 10% Squamous cell carcinoma (MD) 11 C10 40% 65 50% 10% Adenocarcinoma (LD) 12 D1 < 5% 10 50% 25% 13 D7 30% 56 80% 40% 14 D8 20% 29 40% 40% 15 D9 < 5% 3 35% 35% 16 D10 15% 30 20% 40% 17 D18 40% 172 35% 20% Adenocarcinoma (MD) 18 D2 23% 137 60% 60% 19 D4 < 5% 3 ND ND 20 D6 50% 100 60% 60% 21 D14 98% 219 - 25% 22 D16 90% 196 - 70% 23 D17 98% 138 - 10% Adenocarcinoma (MD/LD) 24 D12 50% 110 10% < 5% 25 D13 50% 142 50% 50% AC with regions of solid clear cell cancer 26 D11 35% 64 30% 0.5% 27 D21 100% 150 40% 40% Bronchoalveolar cancer (HD) 28 D19 45% 78 - 3% 29 D20 81% 216 1% - Mixed type (AC + SCC) 30 D15 100% 111 25% 10% Papillary AC 31 D3 10% 81 30% 15% According to the data of IHC analysis, beta-defen- sin-2 is distributed in tumor cell cytoplasm as well as in perinuclear space (Fig. 2). DISCUSSION Involvement of human antimicrobial peptides, in particular, defensins in antimicrobial protection of airways has been in spite of interest of many scientific groups. The patterns of hBD-2 expression in surface epithelial cells of human lung and bronchus has been firstly described in 1998 in the detailed research of Bals et al [7] who have showed hBD-2 up-regulation in conditions of chronic inflammation. In a short time the molecular mechanisms of hBD-2 induction in respira- tory hTBE cells via NF-kB activation with involvement of CD14 and TLR has been reported in the study of Beker et al [8]. Since then, mailfunction or altered levels of defensins have been reported in several pulmonary disorders, in particular, pulmonary fibrosis, panbron- chiolitis, alveolar proteinosis, acute respiratory distress syndrome, lung transplantation, etc [9]; at present time the exact role of defensins, multifunctional molecules with direct antimicrobial activity and immunomodula- tory properties, in lung disorders is not fully understood and remains largely unstudied in lung cancer. To our knowledge, our study is among the first ones where beta-defensin-2 expression has been recorded in human lung tumor samples with the use of immu- nohistochemical analysis. It has been revealed that all lung tumor samples independently on their histological type express hBD-2 peptide, however at different lev- els (from < 5% to 100% cells). In the majority of cases hBD-2 expression is moderate, in 4 cases very low (< 5% cells), and nearly in 1/3 of cases it is very high (close to 100% of cells, or > 200 by H-score). These data are a b c d Fig.1. Immunohistochemical analysis of hBD-2 expression in lung squamous cell carcinoma (cases C4 (a), C5 (b)) and lung ad- enocarcinoma (cases D18 (c), D21(d)) 276 Experimental Oncology 32, 273–276, 2010 (December) in some agreement with observations of Arimura et al. [10] who have recorded significantly elevated concen- trations of hBD-1 and high concentrations of hBD-2 in blood serum of lung cancer patients compared to pa- tients with pneumonia and healthy donors, and the data of our earlier pilot study that has documented the fact that an up-regulation of hBD-1 and hBD-2 mRNAs is a frequent event in both lung SCC and AC compared to normal lung tissue samples [6]. Unfortunately, as far as the data on the history of the patients studied in present study (concominant lung pathologies, smoking habits) were unavailable, there are no grounds to speculate on possible causes of elevated expression of the defensin in lung tumor tissues. The hBD-2 expression levels in these samples seem to be not correlated with expression of prolif- eration marker PCNA and antiapoptotic Bcl-2 pro- tein. Interestingly, we have detected also that in lung adenocarcinoma hBD-2 expression depend on tumor differentiation grade — low differentiated tumors differ from moderately differentiated ones by significantly lower percent of hBD-2 expressing cells (p < 0.05). Functional significance of human defensin-2 up- regulation in lung tumor cells and possible relation between its expression and tumor differentiation grade remain to be studied in further researches. ACKNOWLEDGEMENT The authors wish to express their sincere gratitude to Dr. O.V. Yurchenko (IEPOR NASU) for her expertized assistance and valuable advices in the IHC research. The work was supported in part by NASU grant U002243 “Fundamental Problems of Genomics and Proteomics”. REFERENCES 1. Bullard RS, Gibson W, Bose SK, et al. Functional analysis of the host defense peptide human beta defensin-1: new insight into its potential role in cancer. Mol Immunol 2008; 45: 839–48. 2. Droina N, Hendrab J-B, Ducoroyb P, et al. Human defensins as cancer biomarkers and antitumour molecules. J Proteomics 2009; 72: 918–27. 3. Doss M, White MR, Tecle T, et al. Human defensins and LL-37 in mucosal immunity. J Leukocyte Biol 2010; 87: 79–92. 4. Rogan MP, Geraghty P, Greene CM, et al. Antimicrobial proteins and polypeptides in pulmonary innate defense. Respir Research 2006; 7: 29. 5. Herr C, Beisswenger C, Hess C, et al. Suppression of pul- monary innate host defense in smokers. Thorax 2009; 64: 144–9. 6. Shestakova T, Zhuravel E, Bolgova L, et al. Expression of human beta-defensins-1-4 in human lung tumors: a pilot study. Exp Oncol 2008; 30: 153–6. 7. Bals R, Wang X, Wu Z, et al. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest 1998; 102: 874–80. 8. Becker MN, Diamond G, Verghese MW, et al. CD14- dependent lipopolysaccharide-induced beta-defensin-2 ex- pression in human tracheobronchial epithelium. J Biol Chem 2000; 275: 29731–6. 9. Beisswenger C, Bals R. Antimicrobial peptides in lung inflammation. Chem Immunol Allergy 2005; 86: 55–71. 10. Arimura Y, Ashitani J, Yanagi S, et al. Elevated serum beta-defensins concentrations in patients with lung cancer. Anticancer Res 2004; 24: 4051-7. Copyright © Experimental Oncology, 2010 a b с Fig. 2. Immunohistochemical analysis of hBD-2 expression in lung squamous cell carcinoma (case C7 (a)) and lung adeno- carcinoma (cases D14 (b), D16 (c)) Experimental Oncology 32, 277–279, 2010 (December) 277 Isolated splenic metastasis is rare in colorectal cancer. Malign melanoma, breast and ovarian cancers are the most common solid tumors in which splenic metastasis occurs [1]. Isolated splenic metastasis may be synchronous or metachronous. The rates of iso- lated splenic metastasis are reported as 4.4% for colon cancer and 1.6% for rectum cancer. It is ge nerally diagnosed while evaluating asymptomatic cancer patients with increasing levels of carcinoembryonic antigen (CEA). In this report, our aim is to report two cases with atypical metastasis. Case 1. A 58-year old male patient was admitted to the hospital with ileus a year ago. Hemicolectomy was performed after the diagnosis of colon carcinoma. His- topathology revealed colon adenocarcinoma without lymph node involvement (stage III). He was given adju- vant 5-flurouracil (5-FU)-based chemotherapy. He had a CEA level elevation [4.62 ng/mL (N: 0–3.4)] in blood serum fifteen months after hemicolectomy without any evidence of local or distant metastasis on evaluation. However, a splenic mass was diagnosed 5 months later. Splenectomy was performed, and histopathology revealed the metastasis of colon adenocarcinoma in the spleen. A 3.5 x 3 x 2.5 cm size tumor was located just beneath the capsule of the spleen (Fig. 1, a, b). Chemotherapy which consisted of 5-FU, leucovorine (LV) and oxaliplatin (FOLFOX-4) was given. He had a second relapse in the splenic localization (5.5 x 3 cm) after 11 months of first relapse. An increased uptake of 18-fluorodeoxyglucose (18-FDG) was observed only in this lesion with standardized uptake value (SUVmax) of 11.7 on 18-FDG-positron emission computerized tomography (18-FDG-PET-CT) (Fig. 2). Palliative che- motherapy including 5-FU, LV, irinotecan (FOLFIRI) and bevacizumab was started. The patient has no evidence of progression for 7 months after the second relapse. Case 2. A 51-year old male patient was admitted with 2 months of constipation and hematochezia. He was diagnosed as having rectal adenocarcinoma with bilateral lung metastasis and a solitary nodular lesion (1.8 x 1.5 cm) in the upper pole of right kidney. Renal mass SUVmax was 13.1 on 18-FDG-PET-CT (Fig. 3). Renal aspiration biopsy was performed to determine TWO CASES WITH ATYPICAL METASTASIS IN COLORECTAL CANCER: SPLENIC AND RENAL METASTASIS M. Dogan1,, G. Ozal1, C. Ekinci2, G. Utkan1, Y. Urun1, B. Yalcin1, F. Icli1 1Department of Medical Oncology, Cebeci Hospital, Ankara University School of Medicine, 06590, Dikimevi, Ankara, Turkey 2Department of Pathology, Ankara University School of Medicine, 06590, Sıhhiye, Ankara, Turkey Atypical metastasis, such as splenic and renal metastasis is rare in colorectal cancer. There have been case reports of colorectal cancer patients with isolated splenic metastasis, even after years of surgery in the literature. Aim: To report two colorectal cancer cases with atypical metastasis. Results: The first patient was a 58-year old man who had isolated splenic metastasis after 20 months of surgery. The other one was a 51-year old male patient with both lung and renal metastasis at rectal cancer diagnosis. Splenic and renal metastases have been histopathologically documented in both of them. The first patient was given chemotherapy after splenectomy. The other one had also multiple lung metastases besides renal metastasis. He received palliative chemotherapy. Key Words: atypical metastasis, isolated splenic metastasis, renal metastasis. Received: Correspondence: Fax: +903123192283; E-mail: mutludogan1@yahoo.com Abbreviations used: 5-FU — 5-flurouracil; 18-FDG — 18-fluorodeoxy- glucose; CEA — carcinoembryonic antigen; CT — computerized to- mography; PET-CT — positron emission computerized tomography. Exp Oncol 2010 32, 4, 277–279 CASE REPORT a b Fig. 1. Focal necrosis and atypical prismatic tumor cells with abortive organization, hematoxylin and eosin staining — 10X (a), 40X (b)

Immunohistochemical analysis of beta-defensin-2 expression in human lung tumors

Institution

Ähnliche Einträge